T3 Defense Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on February 24, 2026, and February 25, 2026. T3 Defense Inc. (Nasdaq: DFNS), an emerging growth company, announced a material definitive agreement for a private placement of securities and the resignation of a board member.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard operating financial results. Key metrics include:
- Total Aggregate Purchase Price: $20,000,000 for 400 units.
- Per Unit Price: $50,000.
- Initial Closing Proceeds: $10,000,000 (200 units) scheduled for February 26, 2026.
- Second Closing Proceeds: Up to $10,000,000 (200 units), contingent on specific market and regulatory conditions.
- Placement Fees: 3.5% cash fee plus warrants equal to 7.5% of securities placed.
- Liquidity and Debt: The filing does not provide current cash balances, total debt, or liquidity ratios. The transaction is intended to raise capital.
Material Changes and Transaction Structure
The private placement is structured as a two-stage investment with specific conditions for the second tranche:
- Securities Issued: Each unit consists of one share of Series B Convertible Preferred Stock and 1.5 Common Stock Purchase Warrants.
- Series B Preferred Stock: Stated value of $50,000 per share; initially convertible into 23,474 shares of Common Stock (Initial Conversion Price: $2.13). Includes anti-dilution protections and a 105% redemption option if stockholder approval is not obtained within one year.
- Common Warrants: Initial exercise price of $0.0125 per share; exercisable 180 days post-issuance or upon stockholder approval; expire in 5 years.
- Second Closing Conditions: Requires effectiveness of a registration statement, stockholder approval, a stock price of at least $1.00, and a 10-day average trading value of at least $900,000. If trading value is lower, the unit count is proportionately reduced.
- Corporate Governance Change: Ms. Aviya Volodarsky resigned from the Board of Directors effective February 23, 2026, for personal reasons.
Guidance, Risks, and Contingencies
Management commentary is limited to the terms of the agreement. Key risks and contingencies include:
- Stockholder Approval: The Company must obtain stockholder approval for the issuance. If not obtained at the first meeting, the Company must call meetings every 4 months until approval is granted or securities are retired.
- Registration Rights: The Company must file a registration statement within 45 days and have it declared effective within 75 days. Failure to meet these deadlines triggers liquidated damages of 1.5% of the purchase price per period.
- Lock-Up Agreements: The CEO and directors are locked up for 75% of their holdings for three months following the effectiveness of the registration statement.
- Market Conditions: The second tranche of funding is contingent on the Company's stock price and trading volume meeting specific thresholds.
Investor Verification Checklist
- Verify the status of the stockholder approval vote required for the issuance of Series B Preferred Stock.
- Confirm the filing and effectiveness date of the Initial Registration Statement to assess potential liquidated damages.
- Monitor the 10-day average trading value of DFNS stock to determine if the second $10 million closing will occur in full or be reduced.
- Review the Certificate of Designations for Series B Preferred Stock to understand the specific anti-dilution mechanics and conversion triggers.
- Check for any subsequent filings regarding the resignation of Ms. Volodarsky and the appointment of a replacement director.